Fredrik O L Nilsson

6PUBLICATIONS
10CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Dec 20, 2024
Cost-effectiveness of outpatient COVID-19 antiviral treatment with nirmatrelvir/ritonavir versus usual care in Swedish patients with various risk factors.

Fredrik Nilsson, Martina Aldvén, Christian Gerdesköld Rappe

|Oct 28, 2024
First-line sunitinib treatment modification in patients with mRCC: nationwide analysis of the Swedish population.

Maria Jakobsson, Fredrik Nilsson, Angela Strambi

|Jul 26, 2024
Real-world experience of second-line axitinib in metastatic renal cell carcinoma: analysis of the Swedish population.

Maria Jakobsson, Angela Strambi, Fredrik Nilsson

|May 12, 2023
Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden.

Jaesh Naik, Norma Beavers, Fredrik O L Nilsson

|Nov 11, 2022
Use of ALK-tyrosine kinase inhibitors (ALK TKI) in clinical practice, overall survival, and treatment duration - a Swedish nationwide retrospective study.

Rosa Lauppe, Fredrik O L Nilsson, Hanna Fues Wahl

|Jun 03, 2021
The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden.

Fredrik O L Nilsson, Sandra T Asanin, Elizabeth T Masters

Pageof 1

Frequent Collaborators

2 joint publications

Maria Jakobsson

2 joint publications

Angela Strambi

2 joint publications

Johannes Arpegård

1 joint publications

Martina Aldvén